Nutraceuticals
News Releases
2015
December
Pharmaceuticals
Winner Announced for the 2015 Young Innovator in TB Research Award
Pharmaceuticals
Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Nutraceuticals
Otsuka Pharmaceutical Concludes Comprehensive Agreement for Community Health Initiatives with Fukuoka Prefecture
Nutraceuticals
POCARI SWEAT Launched in Cambodia on December 1, 2015
November
Pharmaceuticals
E Keppra® Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures
Pharmaceuticals
Otsuka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
Nutraceuticals
Nature Made Ginkgo Biloba Otsuka Pharmaceutical Introduces Japan's First Food with Specific Function Claim for Cognitive Functions
Corporate
10,000 Attend 7th Asan Walking Festival in Itano on November 15 Cosponsored by Otsuka Pharmaceutical Tokushima Itano Factory
October
Nutraceuticals
Acquisition of BIOCENTURY, Leading Spanish Health and Functional Food Company
Nutraceuticals
Otsuka Pharmaceutical Named "Best Communicator" 'Heatstroke Prevention Communication Project' Hitosuzumi Awards 2015
Pharmaceuticals
New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
September
August
Nutraceuticals
Three Nature Made Products Receive Foods with Function Claims Labels specify benefits for eyes and inhibition of triglyceride levels in the blood
Nutraceuticals
Omugi Gohan Barley Rice from OMUGI SEIKATSU Receive Food with Function Claims Labels specify three benefits, including control of glucose absorption
Pharmaceuticals
Otsuka Pharmaceutical's Subsidiary Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 in the U.S.
Nutraceuticals
New Pen-type UL·OS Medicated Skin Whitening Helps Men Avoid Dark Spots and Freckles by Inhibiting Melanin Formation
July
Pharmaceuticals
Otsuka Pharmaceutical's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
U.S. FDA Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
Nutraceuticals
Otsuka Pharmaceutical Continues the Overseas Distribution Expansion of POCARI SWEAT East Timor Market Official Launch July 1, 2015
June
May
Pharmaceuticals
Otsuka's JINARC® the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Nutraceuticals
Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong Otsuka Pharmaceutical to Launch Carbonated Nutritional Beverage in Rapidly Growing Hong Kong Market
Pharmaceuticals
New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25
April
Nutraceuticals
Kenja-no-shokutaku Double Support Makes Overseas Debut in Hong Kong
Pharmaceuticals
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry
Nutraceuticals
Review of research on use by menopausal women of nutritional supplement equol appears in US women's health publication
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
March
Pharmaceuticals
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuticals
Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures
Pharmaceuticals
New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
Pharmaceuticals
The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
Nutraceuticals
Celebrating 50 Years of ORONAMIN C DRINK
Nutraceuticals
New SOYJOY With More Fruit! Renewed Strawberry and Blueberry Versions Contain More Fruit
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors (PDF: 41.2 KB)
Nutraceuticals
Otsuka Pharmaceutical, Otsuka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales
Pharmaceuticals
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
February
Pharmaceuticals
CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
Corporate
Otsuka Pharmaceutical Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination
Pharmaceuticals
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures
Nutraceuticals
New UL・OS Facial and Body Wipes
Nutraceuticals
Supporting Tokyo Marathon Runners with Beverages and Nutrition Before, During, and After the Race
Corporate
Notice of Change of Representative Director (Concurrent Obituary) (PDF: 128.1 KB)
Nutraceuticals
Otsuka Pharmaceutical Expands Overseas Distribution of ORONAMIN C DRINK Carbonated nutritional beverage to be produced and sold in South Korea
January
Corporate
Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia
Pharmaceuticals